UK

Maintain your business effective and compliant in the post-Brexit UK market

UK

After the UK’s withdrawal from the European Union took place, the UK regulatory context separated from that of the European Union, what posed a challenge for pharmaceutical companies in order to understand to what extent their market activity would be affected.

This change led to the need of providing support both for adapting past casuistries to the new regulatory environment and to generate strategic projects for new commercialization, such as in:

  • Clinical and pre-approval support
  • Registration and authorisation
  • Post-approval and product maintenance support

Altogether, these services are provided based on the following aspects:

  • Assessment of the regulatory impact and development of a Brexit transition strategy for your company
  • Management of MAH transfers and other necessary variations
  • Continuous update on the regulatory requirements dictated by the MHRA due to Brexit

 

After the UK’s withdrawal from the European Union took place, the UK regulatory context separated from that of the European Union, what posed a challenge for pharmaceutical companies in order to understand to what extent their market activity would be affected.

This change led to the need of providing support both for adapting past casuistries to the new regulatory environment and to generate strategic projects for new commercialization, such as in:

  • Clinical and pre-approval support
  • Registration and authorisation
  • Post-approval and product maintenance support

Altogether, these services are provided based on the following aspects:

  • Assessment of the regulatory impact and development of a Brexit transition strategy for your company
  • Management of MAH transfers and other necessary variations
  • Continuous update on the regulatory requirements dictated by the MHRA due to Brexit

 

Our Solutions

  • National Scientific Advice with MHRA
  • Product designation: Orphan drug designation (ODD) application, ATMPs, Cell and Gene therapies
  • Paediatric Investigational Plans within the UK framework
  • Clinical Trial application
  • Investigator’s Brochure (IB)
  • Generation of clinical evidence to support future registration
  • Support in selection of most convenient indication and target population
  • Elaboration of CTD and other UK-contextualized required technical documents
  • Gap analysis of your current documents and update of CMC, non-clinical and clinical counterparts for UK submission
  • Writing for registration of all types of products within all therapeutic areas: Strong expertise with innovative NCE, ATMPs, Biologicals and Biosimilars
  • Submission in UK using the new National Portal
  • National procedures in UK, accelerated and rolling reviews, national variations
  • Amended packaging and leaflet
  • Baselines for grandfathered products.
  • Management of eSubmissions accepted by MHRA
    •  Comprehensive eCTD services
    • eCTD compilation and publishing
    • Full life-cycle support for Europe, USA, Canada, Switzerland, Saudi Arabia, GCC, and more
    • Information Management (RIMS solution)
    • Software installation, training, validation, support
  • Product maintenance, including update of regulatory dossiers, variations and amendments:
    • Efficiency for variations, renewals, and notifications.
    • Complete portfolio maintenance
    • Management of labelling
    • Promotional material review for UK
  • Local support for pharmacovigilance:
    • Acting as your UK-QPPV:
      • Audit PV System and support for set-up of Quality System
      • Preparation of PSMF, RMP, PSURs, and handling of Case Management
    • Reporting adverse events and submissions of PSURs to MHRA
    • Batch update of all your records with the new QPPV and PSMF information in the Article 57 database
    • Holding your pharmacovigilance system master file at our location
  • Acting as your UK-based MAH
  • Acting as your UK-local contact with MHRA
  • Re-establishing your SME status
  • Responsible Person for Import (RP-I)
  • Assistance with local competent authorities’ communication
  • Product registration
  • Other local requirements
  • Manufacturer and supplier audits
  • QMS self-inspections
  • Notified body mock inspections

Schedule a free meeting!

Discuss your case with our experts and receive a valuable feedback

Share

Why Asphalion?

Asphalion is fully prepared and experienced in acting as a local UK support to successfully manage your relationship with government and medical entities (MAH, MHRA, among others). As such, our experts are aware of the post-Brexit new regulatory requirements.​

In fact, Asphalion counts with an office in the United Kingdom to help manage potential key contacts with regulatory entities to facilitate any administrative issue related to clinical development, registration, commercialization and adequate product maintenance.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.

We will be happy to assist you! 

Schedule a meeting